BioBridge Therapeutics
BioBridge Therapeutics is the translational arm of 4-CYTE– our internal biotech incubator that carries discoveries across the perilous “valley of death” between academia and the clinic. In BioBridge, promising research findings don’t sit idle; they are nurtured, developed, and propelled toward therapies. This unit operates like a startup but within the safe confines of a supportive university, pushing forward preclinical studies,
drug development, and prototype testing with the rigor and urgency found in industry.
The core purpose of BioBridge is to bridge the gap between advanced discoveries and therapeutic development– ensuring that a novel insight in the lab can become a tangible treatment for patients. The team designs proof-of-concept experiments, navigates patent and regulatory pathways, and forms partnerships to move innovations into clinical trials. Driven by impact rather than profit, BioBridge champions therapies that offer the greatest benefit to patients, even when financial returns are uncertain. By focusing on societal need rather than just commercial appeal, BioBridge Therapeutics exemplifies 4-CYTE’s values.
The Core Functions of BioBridge Therapeutics
BioBridge will advance groundbreaking clinical trials for novel treatments targeting substance use disorder, schizophrenia, depression, and trichotillomania. For each condition, the team:
-
Designs state-of-the-art clinical studies that integrate modern science, AI-driven precision medicine, and innovative trial methodologies to maximize trial success.
-
Builds academic-industry partnerships capable of executing each study
-
Submits competitive NIH grant proposals to fund each trial
-
Upon securing funding, BioBridge oversees these collaborations, ensuring the trials are conducted with scientific rigor and efficiency.
© 2035 by 4-CYTE.
Schroeder Complex
Marquette University
560 N 16th St
Milwaukee, WI, 53233, USA